Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01427322 · ClinicalTrials.gov registry record · Early Phase 1
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01427322 is a Early Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 6 participants.
The verdict
NCT01427322, a Early Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Lapatinib will prevent radiation-induced increase in Transforming Growth Factor alpha (TGFα), an important growth factor in cancer cell recovery after ionizing irradiation.
Interventions
- RADIATION Radiation therapy
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01427322
The ClinicalTrials.gov registry entry for NCT01427322 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation therapy is the first listed.
NCT01427322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01427322 about?
NCT01427322 is a clinical study titled "Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease". Lapatinib will prevent radiation-induced increase in Transforming Growth Factor alpha (TGFα), an important growth factor in cancer cell recovery after ionizing irradiation.
What is the current status of trial NCT01427322?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2011-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01427322?
The interventions under investigation include: Radiation therapy (RADIATION), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01427322?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.